Actuate Therapeutics (NASDAQ:ACTU) Stock Price Up 4.5% – Here’s What Happened

Actuate Therapeutics (NASDAQ:ACTU) was up 4.5% on Friday . The stock traded as high as $7.26 and last traded at $7.24. Approximately 24,047 shares traded hands during trading, a decline of 22% from the average daily volume of 30,717 shares. The stock had previously closed at $6.93.

Actuate Therapeutics Trading Up 4.5 %

The company has a fifty day moving average of $8.34 and a two-hundred day moving average of $8.17.

Institutional Investors Weigh In On Actuate Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BIOS Capital Management LP purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $78,753,000. Voss Capital LP purchased a new position in shares of Actuate Therapeutics during the fourth quarter valued at approximately $440,000. Northwestern University bought a new position in shares of Actuate Therapeutics during the third quarter valued at approximately $207,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Actuate Therapeutics in the fourth quarter worth approximately $130,000. Finally, Sigma Planning Corp bought a new stake in shares of Actuate Therapeutics during the 4th quarter worth approximately $128,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.